Eczema herpeticum after topical JAK inhibition: Eczema Herpeticum Following Topical Ruxolitinib Use: A Report of Two Cases Zhang K et al. Annals of Allergy, Asthma & Immunology. 2026. ➜ DOI: 10.1016/j.anai.2026.06.016
Why it matters: Eczema herpeticum is one of the most clinically important infectious complications of AD. These two cases are noteworthy because they occurred following treatment with topical ruxolitinib, reminding us that topical administration does not necessarily mean absence of meaningful local immunological effects. JAK signalling contributes to interferon-mediated antiviral defence. Its inhibition in skin with an already impaired barrier and altered antiviral response could plausibly favor local herpes simplex virus propagation in susceptible patients.
Context and caution: Two cases cannot demonstrate causality or determine the magnitude of risk. Important contextual factors include previous eczema herpeticum, the extent and location of treated skin, barrier disruption, concomitant immunomodulatory therapy and the possibility that severe AD itself accounted for susceptibility. The cases should therefore be interpreted as a signal requiring surveillance rather than evidence that topical ruxolitinib commonly causes eczema herpeticum.
Bottom line: “Topical” does not necessarily mean immunologically trivial.
Ubiquitination enters the mast-cell signalling network HECT E3 Ubiquitin Ligase SMURF2 Orchestrates FcεRI-Dependent Mast Cell Activation and Allergic Responses Liang J et al. Journal of Allergy and Clinical Immunology. 2026. ➜ DOI: 10.1016/j.jaci.2026.06.001 – PMID: 42285366.
Why it matters: Mast-cell activation is usually described as a relatively direct sequence from IgE cross-linking and FcεRI signalling to mediator release. This study identifies SMURF2, a HECT-type E3 ubiquitin ligase, as a positive regulator of this response. SMURF2 promotes the degradation of NEDD4L, thereby amplifying Syk-dependent signalling, mast-cell activation and experimental allergic responses. The work expands the field beyond extracellular cytokines and receptors to the intracellular systems controlling protein stability and signal duration.
Context and caution: The relevance of this pathway to human AD remains uncertain. Mast cells contribute to itch and allergic responses, but they are only one component of the complex AD inflammatory network. Pharmacological manipulation of ubiquitination may also have broad and unpredictable effects because these enzymes regulate numerous cellular pathways. Considerable validation will therefore be required before this mechanism becomes a realistic therapeutic target.
Bottom line: The intensity of allergic inflammation may depend as much on intracellular protein regulation as on extracellular cytokines.
The epidermis as an organizer of inflammation The LCE3D/TGF-β1 Axis in Atopic Dermatitis: Expression Profiling, Clinical Significance, and Mechanistic Insights Into Epithelial–Immune Crosstalk Li Q et al. Clinical Immunology. 2026. ➜ DOI: 10.1016/j.clim.2026.110748
Why it matters: Late cornified envelope proteins are generally associated with epidermal differentiation and barrier formation. This study links LCE3D to TGF-β1-dependent epithelial–immune communication, supporting the concept that the epidermis is not merely damaged by inflammation but actively participates in organizing it. The paper fits an increasingly important view of AD in which keratinocyte differentiation, barrier repair and immune signalling are closely interconnected rather than forming separate pathogenic compartments.
Context and caution: Changes in LCE3D expression may be causal, compensatory or simply secondary to inflammation and epidermal repair. Associations with clinical severity do not by themselves establish that the pathway initiates disease. Independent cohorts and functional human studies will be needed to determine whether LCE3D identifies a genuine endotype, a marker of epidermal stress or a therapeutically relevant pathway.
Bottom line: The AD epidermis does not simply receive inflammatory signals—it may help generate and organize them.
Household endotoxin, house-dust mite exposure and AD Association Between Household Endotoxin Exposure and Atopic Dermatitis: A Cross-Sectional U.S.-Based Population Study Quan I et al. Journal of Investigative Dermatology. 2026. ➜ DOI: 10.1016/j.jid.2026.06.1290
Why it matters: Using a nationally representative U.S. sample, the authors examined household endotoxin—lipopolysaccharide from Gram-negative bacteria—in relation to AD and assessed how this association was modified by house-dust mite exposure. The results were not consistent with a simple linear “more endotoxin is protective” model. Endotoxin exposure was associated with AD differently according to the accompanying level of mite allergen, indicating an interaction between microbial products and allergen exposure rather than two independent effects. This refines the hygiene hypothesis. LPS may promote immune training or tolerance in some settings, while substantial HDM exposure may alter that response in an already sensitized host. The household exposome—the mixture, timing and intensity of LPS and HDM exposure—may therefore be more informative than either measurement considered alone.
Context and caution: The study is cross-sectional, so it cannot determine whether the measured exposures preceded AD, influenced persistence, or were modified by family behaviour after diagnosis. A single dust sample is also an imperfect surrogate for long-term inhaled and cutaneous exposure, and endotoxin levels correlate with pets, housing, cleaning practices, socioeconomic conditions and other microbial or allergenic components. The findings should not be translated into recommendations to increase or reduce domestic endotoxin or mite exposure. Their value lies in showing that environmental effects on AD are conditional and interactive, not uniformly protective or harmful.
Bottom line: In AD, LPS and house-dust mite exposure appear to form a combined environmental signal, not two independent variables.
OX40 inhibition and Kaposi sarcoma: a biologically plausible safety signal OX40 Pathway Inhibition and Kaposi Sarcoma: An Emerging Safety Signal in Atopic Dermatitis Devocht B et al. Journal of the European Academy of Dermatology and Venereology. 2026. ➜ DOI: 10.1111/jdv.70585 – PMID: 42317069.
Why it matters: The OX40–OX40L pathway has become an important therapeutic target in AD because of its role in T-cell activation, survival and memory. Reports of Kaposi sarcoma during OX40 or OX40L pathway inhibition are therefore particularly important and may represent more than a coincidental pharmacovigilance observation. More than a decade ago, congenital OX40 deficiency was identified in a patient with aggressive childhood-onset Kaposi sarcoma. Impaired OX40 signalling compromised CD4-positive T-cell memory and immune control of human herpesvirus 8, providing direct human evidence that this pathway contributes to surveillance against HHV-8-associated disease. Experimental studies have also shown that OX40–OX40L engagement can directly inhibit HHV-8 lytic replication in endothelial cells. Together, these observations provide a biologically plausible explanation for why disruption of the pathway might facilitate HHV-8 reactivation or loss of control in susceptible individuals.
Context and caution: Kaposi sarcoma remains a rare event, and individual reports cannot establish its incidence or prove a causal relationship with OX40-pathway inhibition. Background HHV-8 prevalence varies markedly according to geography, ancestry and epidemiological setting, and other causes of immune dysfunction must be considered. It is also important not to assume that all OX40- and OX40L-targeting antibodies have identical biological effects. Their influence on receptor signalling, ligand blockade, cell depletion and T-cell subsets may differ. Nevertheless, the convergence of clinical reports, congenital human OX40 deficiency and experimental evidence concerning HHV-8 control makes this signal particularly compelling. Clinicians should remain attentive to persistent violaceous papules, plaques or nodules, especially in patients with epidemiological risk factors for HHV-8.
Bottom line: The OX40 pathway may be a therapeutic target in AD, but it also appears to contribute to immune surveillance of HHV-8.
